Trial reportBlood2009
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
Trial report in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 105 citations in OpenAlex.
- Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Bone marrow transplantation · 2016Trial
- Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.Bone marrow transplantation · 2015Trial
- Trial
- Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913).Cancer research and treatment · 2024Article
- The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.Clinical hematology international · 2023Article
- Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol.PloS one · 2023Article
- Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2022Review
- Review
- Article
- Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?Journal of clinical medicine · 2020Review
- The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?Haematologica · 2019Article
- Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.Haematologica · 2019Article
- Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Cancer cell international · 2018Article
- Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Bone marrow transplantation · 2017Article
- Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Current hematologic malignancy reports · 2017Review
- Allogeneic stem cell transplantation for multiple myeloma: is there a future?Bone marrow transplantation · 2016Review
- Allogeneic transplantation for multiple myeloma: yes, no or maybe?Bone marrow transplantation · 2016Article
- The role of physical rehabilitation in stem cell transplantation patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Review
- Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.Bone marrow transplantation · 2015Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 12 institutions in 3 countries.
Funding
Abstract
Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycophenolate mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, beta-2-microglobulin of more than 3.5 microg/mL at diagnosis and auto/alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.